Pharmaceutical - Inflammatory diseases, Oncology

Filter

Popular Filters

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

06-01-2014

Privately-held German company Probiodrug says it has transferred its experimental cyclin-dependent kinase…

AstraZenecaInflammatory diseasesMergers & AcquisitionsOncologyPharmaceuticalProbiodrug

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development

05-11-2013

At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

AstraZeneca plans more job cuts; inks $240M-plus deal with Moderna; expands alliance with Karolinska Institutet

21-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN), ahead of its Investor Day briefing in New York later…

AstraZenecaCardio-vascularFinancialImmunologicalsInflammatory diseasesLicensingModerna TherapeuticsOncologyPharmaceuticalResearch

Immune Pharmaceuticals to acquire EpiCept under stock merger accord

08-11-2012

Privately-held Israeli company Immune Pharmaceuticals and US drug developer EpiCept Corp (Nasdaq: EPCT)…

EpiCeptImmune PharmaceuticalsInflammatory diseasesMergers & AcquisitionsOncologyPharmaceutical

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S

10-10-2012

Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb

05-10-2012

USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

MannKind licenses novel BTK inhibitors to Tolero Pharma

01-05-2012

USA-based MannKind Corp (Nasdaq: MNKD) has granted an exclusive worldwide license to privately-held Tolero…

Inflammatory diseasesLicensingMannKindOncologyPharmaceuticalTolero Pharmaceuticals

Merck buys in Exelixis’ PI3K-Delta program; returns product to Acumen

22-12-2011

California-based Exelixis (Nasdaq: EXEL) says it has granted US drug giant Merck & Co (NYSE: MRK) an…

Acumen PharmaceuticalsExelixisInflammatory diseasesLicensingMerck & CoNeurologicalOncologyPharmaceutical

BioLineRx inks deal with Compugen

14-12-2011

Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor

01-12-2011

Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

Back to top